Economic evaluation of a new antiemetic drug - Palonosetron versus ondansetron: Assessment of the drug price ratio in five European countries

Clinical Drug Investigation

Volumn 25, Issue 9, 2005, Pages 597-608

  Tarricone, Rosanna ^a   Girolami, Federica ^a  

^a BOCCONI UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; ONDANSETRON; PALONOSETRON;

ARTICLE; CALCULATION; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; EUROPE; GERMANY; HOSPITAL; HOSPITAL COST; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RUSSIAN FEDERATION; SAMPLE SIZE; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

EID: 25644441849     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525090-00005     Document Type: Article

References (28)

1. Jönsson V, Clausen SR, Hansen MM. Pharmacoeconomic as-pects in the treatment of curable and incurable cancer. Pharmacoeconomics 1995; 8: 275-81
2. Uyl-de Groot CA, Wait S, Buijt I. Economics and health-related quality of life in antiemetic therapy: recommendation for trial design. Eur J Cancer 2000; 36: 1522-35
3. De Boer-Dennert M, de Wit R, Schmitz PI, et al. Patient perception of the side-effects of chemotherapy: the influence of 5-HT3 antagonists. Br J Cancer 1997; 76: 1055-61
4. Gralla R. Management of nausea and vomiting. Cancer Management: A multidisciplinary approach. European Commission DG Enterprise and Industry - Directorate F - Consumer goods, 2001
5. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004 May 15; 100 (10): 2261-8
6. Pendergrass KB. Options in the treatment of chemotherapy induced emesis. Cancer Pract 1998; 6: 276-81
7. Grunberg SM. Cost-effective use of antiemetics. Oncology 1998; 12: 38-42
8. Bradbury RP. Chemotherapy induced nausea and vomiting: rationale for cost effective management. Cancer Control 1996; 3 (3): 242-9
9. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000; 18: 163-73
10. Lachaine J, Laurier C, Langleben A, et al. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. Crit Rev Oncol Hematol 1999; 32 (2): 105-12
11. Lachaine J, Laurier C. Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy. Am J Hosp Pharm 2002; 59: 1837-46
12. Ballatori E, Roila F, Berto P, et al. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. Pharmacoeconomics 1994; 5: 227-37
13. Zbrozek AS, Cantor SB, Cardenas MP, et al. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994; 51 (15): 1555-63
14. Plosker GL, Milne RJ. Ondansetron-pharmacoeconomic and quality of life evaluation of its antiemetic activity in patients receiving cancer therapy. Pharmacoeconomics 1992; 2: 285-302
15. Cunningham D, Gore M, Davidson N, et al. The real cost of emesis: an economic analysis of ondansetron versus metoclopramide in controlling emesis of patients receiving chemotherapy for cancer. Eur J Cancer 1993; 29A: 303-6
16. Stewart DJ, Dahrouge S, Coyle D, et al. Cost of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 1999; 17 (1): 344-51
17. Bruggenjurgen B, du Bois A. Effectiveness and cost of 5-HT3 antagonists in acute chemotherapy induced emesis: health economic analysis based on current meta-analytic data. Med Klin (Munich) 1997; 92: 747-52
18. Jones AL, Lee GJ, Bosanquet N. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy induced emesis. Eur J Cancer 1992; 29A: 51-6
19. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-7
20. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997
21. Gralla RJ. Antiemetic therapy. In: Bast RC, Kufe DW, Pollock RE, et al., editors. Holland & Frei Cancer Medicine. 5th ed. American Cancer Society. London: B.C. Decker Inc., 2000
22. Buxton MJ, O'Brien BJ. Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. Br J Cancer 1992; 66: S64-7
23. Le Pen C, Priol G, Lilliu HG. What criteria for pharmaceutical reimbursement? An empirical analysis of the evaluation of 'medical service rendered' by reimbursable drugs in France. Eur J Health Econ 2003; 4: 30-6
24. McGuire A, Drummond A, Rutten F. Reimbursement of pharmaceuticals in European Union. In: Mossialos E, Mrazek M, Walley T, editors. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. European Observatory of Healthcare Systems. Oxford: Open University Press, 2004
25. http://pharmacos.eudra.org/F3/g10/docs/tes/Russia.pdf
26. Jommi C. L'Agenzia Italiana del Farmaco: peculiarità rispetto al contesto europeo ed ai processi di modernizzazione della pubblica amministrazione. Economia e politica del farmaco 2005; 3: 11-6
27. Drummond MF, Joensson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997; 40: 199-215
28. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centres. Ann Oncol 2004; 15: 526-36